



**HAL**  
open science

## Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant -positive cells

Aleksandar Radujkovic, Stefan Fruehauf, W. Jens Zeller, Anthony D. Ho, Julian Topaly

### ► To cite this version:

Aleksandar Radujkovic, Stefan Fruehauf, W. Jens Zeller, Anthony D. Ho, Julian Topaly. Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant -positive cells. *Cancer Chemotherapy and Pharmacology*, 2009, 66 (2), pp.255-264. 10.1007/s00280-009-1158-7. hal-00568274

**HAL Id: hal-00568274**

**<https://hal.science/hal-00568274>**

Submitted on 23 Feb 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Synergistic activity of nilotinib and established chemotherapeutic drugs in  
imatinib-sensitive and -resistant *BCR-ABL*-positive cells**

**Running title: Combination therapy of CML employing nilotinib**

Aleksandar Radujkovic<sup>1</sup>, Stefan Fruehauf<sup>2</sup>, W. Jens Zeller<sup>3</sup>, Anthony D. Ho<sup>1</sup>,  
and Julian Topaly<sup>1,2</sup>

<sup>1</sup>Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

<sup>2</sup>Center of Tumor Diagnostics and Therapy, Paracelsus Clinic, Osnabruck, Germany

<sup>3</sup>Research Group Pharmacology of Cancer Treatment, German Cancer Research Center,  
Heidelberg, Germany

Correspondence:

Dr. med. Julian Topaly

Center of Tumor Diagnostics and Therapy

Paracelsus-Klinik

Am Natruper Holz 69

49076 Osnabruck, Germany

Phone: +49 (0)541/ 9663044

Fax: +49 (0)541/ 9663046

E-mail: julian.topaly@pk-mx.de

Word counts: Abstract: 172 words, Manuscript: 3442 words

Key words: BCR-ABL, nilotinib, combination treatment,  
imatinib resistance, synergism

## ABSTRACT

We investigated various combination treatment regimens employing nilotinib with established chemotherapeutic agents (daunorubicin, mitoxantrone, etoposide and cytarabine) in imatinib-sensitive and -resistant *BCR-ABL*-positive cells. Mitoxantrone or cytarabine showed synergism ( $CI < 1$ ) in combination with nilotinib in imatinib-sensitive LAMA84 cells, whereas in imatinib-resistant LAMA84-R cells synergistic effects could be assessed for daunorubicine, mitoxantrone and etoposide when combined with nilotinib. In both imatinib-sensitive and -resistant K562 cells daunorubicin, mitoxantrone and etoposide demonstrated synergism in combination with nilotinib. Moreover, both daunorubicin and mitoxantrone led to synergistic antiproliferative effects when combined with nilotinib in imatinib-resistant Ba/F3 cells carrying point mutations in the ABL TK domain (E255K, E255V and T315I). Annexin V / propidium iodide staining revealed a significant enhancement of nilotinib-induced apoptosis in imatinib-resistant Ba/F3T315I and LAMA84-R cells upon combination with daunorubicine and mitoxantrone, respectively. Our results demonstrate the efficacy of combination treatment regimens employing nilotinib and established chemotherapeutic agents in improving antileukemic effects in imatinib-sensitive and imatinib-resistant cells. This may be the foundation for further study on the potential of the applied combinations in a clinical setting.

## INTRODUCTION

Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disease characterized by the chromosomal translocation t(9;22)(q34;q11) known as the Philadelphia (Ph<sup>1</sup>) chromosome [1-3]. On the molecular level this aberration leads to the expression of the *BCR-ABL* fusion proto-oncogene with transforming potency due to deregulated ABL tyrosine kinase (TK) activity [3,4]. The development and application of imatinib targeting the ABL TK has revolutionized the treatment of CML making imatinib the therapeutic gold standard for this disease [5,6]. However, resistance to imatinib may evolve in some patients. Up to now various molecular mechanisms of resistance have been described, most notably mutations in the BCR-ABL TK domain and an increased BCR-ABL activity resulting from gene amplification, up-regulation, or multiple Ph chromosomes [7-10]. Consequently, the effort to overcome imatinib resistance within current treatment strategies lead to the development of second-generation TK inhibitors (TKI).

Nilotinib is a potent, second generation aminopyrimidine ATP-competitive inhibitor of BCR-ABL. It has been shown not only to be at least 20-fold more potent in killing cells with non-mutated BCR-ABL *in vitro* than imatinib but also to inhibit the activity of the majority of mutant forms of BCR-ABL occurring in imatinib-resistant patients. [11,12]. Furthermore, recent clinical trials found nilotinib effective and safe in patients with CML post imatinib failure or intolerance [13,14]. However, the efficacy of nilotinib and other newer TK inhibitors is best in the chronic phase of CML and decreases with disease evolution to further stages. In particular, the blast crisis remains a serious clinical challenge [15,16]. With either conventional intensive chemotherapy or the newer targeted therapies applied as single treatment long-term survival in myeloid blast crisis is rare reaching a plateau at under 10% if the patients are not offered a subsequent allogeneic stem cell transplantation upon achievement of response. On the other hand, an induction therapy leading to remission of blast crisis or to restoration of chronic phase was shown to be associated with improved outcome in patients receiving an allogeneic transplant [17].

A number of preclinical studies by several investigators including our group could comprehensively show that combination treatment regimens, employing a TK inhibitor (imatinib) and substances with a differing mode of action, lead to synergistic antiproliferative effects presenting a feasible strategy to increase the antileukemic efficacy and to circumvent imatinib resistance [18-27]. In order to elucidate whether these observations can be translated to nilotinib, in the present study we investigated several combinations applying nilotinib and

established chemotherapeutic agents (daunorubicin, mitoxantrone, etoposide and cytarabine) in different imatinib-sensitive and in particular imatinib-resistant BCR-ABL-positive leukemia cell lines.

## **MATERIALS AND METHODS**

### **Cell lines and culture conditions**

K562 and LAMA84 cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) and were all sensitive to submicromolar concentrations of imatinib [21,22]. The imatinib-resistant cell lines LAMA84-R and K562-R were provided by Professor Junia Melo (London; UK) and were characterized in detail previously [21]. BCR-ABL-positive *wild type* (wt) Ba/F3<sub>wt</sub> cells expressing p185<sup>BCR-ABL</sup> and the corresponding imatinib-resistant lines carrying mutations in the ABL TK domain (E255K, E255V and T315I) were established in the lab of Professor Justus Duyster (Munich, Germany) [28].

All cells were grown in RPMI-1640 medium supplemented with 10% heat inactivated fetal calf serum (FCS), 2 mM L-glutamine and penicillin / streptomycin (Invitrogen, Karlsruhe, Germany) at standard conditions (37°C, fully humidified atmosphere of 95% air and 5% CO<sub>2</sub>). In addition, LAMA84-R and K562-R cells were cultured in medium containing 1 μM imatinib.

### **Drugs**

Nilotinib was kindly provided by Novartis Pharma (Basel, Switzerland). Daunorubicin (DNR; Sigma, Steinheim, Germany), mitoxantrone (Sigma), etoposide (Bristol Arzneimittel, Munich) and cytarabine (Ara-C; Cell Pharm, Hannover, Germany) were purchased from the manufacturers. Nilotinib was initially dissolved in sterile 10% dimethyl sulfoxide solution (DMSO; Merck, Darmstadt, Germany). Other applied cytostatic drugs were dissolved in phosphate-buffered saline (Dulbecco's PBS; Invitrogen). Stock solutions at a concentration of 10 mM of each drug were prepared and stored at -20°C until use. For experiments, serial working dilutions were prepared.

### **Cell proliferation assay and analysis of drug effects and interactions**

MTT assays were used for the assessment of cell proliferation with minor modifications as described previously [18,21]. After 48 h of incubation with tested drugs means of four

replicate wells for each drug dilution and the control (cells grown in absence of the drug) were used to calculate the extent of relative cell proliferation and growth inhibition (defined as fraction affected (Fa) [18]). Each cell line was treated with five increasing concentrations (doubling with each increment) of nilotinib and chemotherapeutic drug alone or their combination, respectively. Since nilotinib, in contrast to the other agents, was dissolved in 10% DMSO the serial drug dilutions and controls were prepared to finally achieve 0.05% DMSO in all wells (control, single agent and drug combinations; total volume 100  $\mu$ l). At this concentration no anti-proliferative effects of the applied DMSO solution could be observed in the investigated cell lines (data not shown).

Dose-effect relationships and drug interactions upon combination of nilotinib and established drugs were analyzed according to the median-effect method of Chou and Talalay [29] employing the CalcuSyn Software (Biosoft, Cambridge, UK). For single agent treatment mean IC<sub>50</sub> values for each drug and cell line were calculated; for combinations mean combination index (CI) values based on equitoxic drug ratios were assessed with CI < 1, CI = 1 or CI > 1 representing synergistic, additive. or antagonistic effects of the substances, respectively and combination data were depicted as CI vs. Fa plots [18,20]. In cell lines where no antiproliferative activity upon single agent treatment was assessable, an analysis in terms of sensitization (potentiation) or inhibition of nilotinib activity was performed instead with relative IC<sub>50</sub> > 1 indicating inhibition and relative IC<sub>50</sub> < 1 indicating potentiation of nilotinib activity, respectively (for details see Topaly *et al* [20] and Radujkovic *et al* [22]).

### **Apoptosis assay**

Assessment of apoptosis rates was done by Annexin V / propidium iodide (PI) staining using the Annexin V-FITC Kit (Immunotech, Marseille, France) 48 h after start of incubation as described previously [21,22]. Data collection and analysis were performed with a FACScalibur flow cytometer (Becton Dickinson, Heidelberg, Germany) applying the CellQuest Software (Becton Dickinson).

### **Statistics**

Three to five independent experiments were performed and the results were depicted as mean value  $\pm$  standard deviation (s.d.). Statistical significant differences of the data were calculated using the Student t test with significance levels of  $p < 0.05$  and  $p < 0.01$ .

## RESULTS

### Single agent treatment

Imatinib-sensitive LAMA84 and K562 cells were all sensitive to nanomolar concentrations of single agent nilotinib (Table I). In the imatinib-resistant counterparts LAMA84-R and K562-R substantially higher nilotinib concentrations for corresponding antiproliferative effects were required. Imatinib-resistant K562-R cells displayed a remarkable resistance towards nilotinib with an IC<sub>50</sub> value of **21,972 nM**, i.e. approximately 600-fold higher than in the respective imatinib-sensitive K562 cells (34 nM); in the LAMA84-R line the IC<sub>50</sub> value (124 nM) was 10-fold higher as compared to the parental line (11 nM). In imatinib-resistant Ba/F3 cells exhibiting point mutations in the BCR-ABL TK domain Ba/F3<sub>E255K</sub>, Ba/F3<sub>E255V</sub> and Ba/F3<sub>T315I</sub> the IC<sub>50</sub> values of nilotinib were 365 nM, 791 nM and **23,582 nM**, respectively, i.e. about 16-, 34- and 1,000-fold higher than in the corresponding parental imatinib-sensitive Ba/F3<sub>wt</sub> cell line (Table I).

Daunorubicin, mitoxantrone and etoposide displayed a concentration dependent inhibition of proliferation after a 48 h treatment. Both intercalating drugs, the anthracycline daunorubicin and the anthracendione mitoxantrone, showed similar antiproliferative effects in LAMA84 cells (Table I). In imatinib-resistant LAMA84-R cells considerably higher concentrations of both agents were necessary for growth inhibition as compared to the imatinib-sensitive LAMA84 line with mitoxantrone and daunorubicin IC<sub>50</sub> values being increased by 10- and 20-fold, respectively, implying cross-resistance towards both compounds (Table I). Regarding imatinib sensitivity, no significant differences in the cytotoxicity of the substances could be observed in K562 cells. The activity of etoposide was substantially higher in the LAMA84 cells as compared to K562 with both imatinib-resistant cell lines (LAMA84-R and K562-R) showing a reduced sensitivity (not significant) towards etoposide (Table I). For cytarabine, only in imatinib-sensitive LAMA84 cells an IC<sub>50</sub> value of 175 nM was calculable; in LAMA84-R cells and in the K562 pair no cytarabine activity could be detected. Daunorubicin displayed similar effects on the growth of all investigated Ba/F3 lines; the same applies to mitoxantrone (Table I).

### Combination treatment

In the imatinib-sensitive LAMA84 cell line combination treatment with nilotinib plus daunorubicin and nilotinib plus etoposide led to antagonistic (CI > 1; Figure 1a) and additive

(CI ~ 1; Figure 1e) effects, respectively. In contrast, the combinations employing mitoxantrone and cytarabine were both clearly synergistic denoted by CI values < 1 above the growth inhibition level > 60% (Fa>0.6) (Figure 1c and g). Combination treatment of imatinib-resistant LAMA84-R cells resulted in enhanced antiproliferative effects for every regimen. Analysis of combined effects revealed synergism with CI values of  $0.36\pm 0.35$ ,  $0.59\pm 0.24$  and  $0.91\pm 0.07$  for nilotinib plus daunorubicin, nilotinib plus mitoxantrone and nilotinib plus etoposide, respectively, at the 60% growth inhibition level (Fa=0.6) (Figure 1b, d, f). Since cytarabine was inactive in LAMA84-R cells (Table I), the median-effect method was not applicable for investigating combination effects. However, non-cytotoxic doses of cytarabine ( $\geq 1,250$  nM) led to a significant reduction of nilotinib IC50 values (relative IC50<1) signifying potentiating of nilotinib activity (Figure 1h).

In imatinib-sensitive K562 cells daunorubicin and mitoxantrone showed synergistic effects when combined with nilotinib at  $Fa\geq 0.4$  and  $Fa>0.3$ , respectively (Figure 2a and c); nilotinib plus etoposide acted synergistically at  $Fa<0.8$  (Figure 2e). In the imatinib-resistant K562-R line combination treatment employing daunorubicin and etoposide displayed synergism (Figure 2b and f) whereas the combination nilotinib plus mitoxantrone was at best additive at  $Fa=0.6$  (Figure 2d). In both imatinib-sensitive and -resistant K562 cells no significant potentiation of nilotinib activity could be observed by cytarabine (Figure 2g and h).

Combination treatment of imatinib-sensitive Ba/F3<sub>wt</sub> cells with nilotinib plus daunorubicin and nilotinib plus mitoxantrone resulted in improved antiproliferative effects as compared to the respective monotherapies with CI values indicating synergism above affected fractions  $\geq 0.45$  and  $Fa>0.3$ , respectively (Figure 3a, b). Depending on the level of growth inhibition the combination nilotinib plus daunorubicin showed synergistic cytotoxic effects also in the imatinib-resistant Ba/F3<sub>E255K</sub> ( $Fa\geq 0.65$ ), Ba/F3<sub>E255V</sub> ( $Fa>0.15$ ) and Ba/F3<sub>T315I</sub> ( $Fa>0.7$ ) cell lines (Figure 3c, e and g). For the combination nilotinib plus mitoxantrone synergistic effects were discernible with CI values < 1 above  $Fa>0.7$  in Ba/F3<sub>E255K</sub> and above  $Fa\geq 0.2$  in both Ba/F3<sub>E255V</sub> and Ba/F3<sub>T315I</sub> cells (Figure 3d, f and h).

### **Induction of apoptosis**

Monotherapy of the imatinib-resistant cell lines K562-R and LAMA84-R with low dose nilotinib, daunorubicin or mitoxantrone increased the early apoptotic cell fractions (Annexin V+ / PI- cells) as compared to untreated controls. For  $1,000$  nM daunorubicin this effect was more obvious with apoptotic fractions of 18% (K562-R) and 15% (LAMA84-R) as compared to nilotinib- (13% and 11%) and mitoxantrone-induced apoptosis (10% and 8%) in the



respective lines. Compared to the corresponding monotherapies drug combinations led to enhanced apoptosis levels (16% - 23%) with a significant increase for nilotinib plus mitoxantrone in the LAMA84-R cell line (Figure 4a).

In the investigated imatinib-resistant Ba/F3<sub>E255K</sub> and Ba/F3<sub>T315I</sub> cells, respectively, only a marginal increase in the proportion of apoptotic cells upon administration of low dose single agent nilotinib (9% and 4%), daunorubicin (6% for both lines) and mitoxantrone (5% and 6%) could be observed as compared to untreated controls (4% and 3%, Figure 4b). Co-treatment of Ba/F3<sub>E255K</sub> cells increased the early apoptotic cell fractions for both combinations (34% for nilotinib plus daunorubicin and 21% for nilotinib plus mitoxantrone). However, only in the Ba/F3<sub>T315I</sub> cell line a significant enhancement of apoptosis could be observed after treatment with the combination nilotinib plus daunorubicin vs. monotherapy (Figure 4b).

## DISCUSSION

Our preclinical studies with combinations of imatinib and classic chemotherapeutic drugs demonstrated significant synergistic action that translated in a better efficacy in a clinical setting in myeloid blast crisis of CML [30]. To present, the majority of patients who progress to a blast crisis of CML have been pre-exposed to imatinib treatment at earlier disease stages and harbor a cell clone resistant to this drug. Several studies demonstrated that BCR-ABL signaling remains one of the principal mechanisms of disease pathogenesis in imatinib resistance. In cases of BCR-ABL TK mutations that confer imatinib-resistance or in cases of up-regulated TK activity as compared to wild type BCR-ABL the newer more potent ABL kinase inhibitors are the rational treatment following imatinib failure.

However, in the course of disease evolution additional pathophysiological mechanisms may gain an increasing influence on cell proliferation thus diminishing the efficacy of single agent TK inhibitors in blast crisis. The logical action to overcome drug resistance is the use of drug combinations with different mechanisms of action. In the present study we investigated the effects of classical chemotherapeutic drugs cytarabine, daunorubicin, etoposide, and mitoxantrone that are typically used in the treatment of acute leukemia. The drugs were used as single agents and as combination partners for nilotinib in imatinib-sensitive CML cells and in BCR-ABL-positive leukemia cells with defined BCR-ABL TK mutations or other mechanisms of imatinib-resistance.

In our previous published reports the effects of imatinib treatment as a single agent and in combination with various compounds were studied extensively both in imatinib-sensitive and -resistant cells [18,19,21,22]. Compared to imatinib treatment, the single agent nilotinib

showed an improved efficacy in the investigated imatinib-sensitive cell lines, reflected by IC50 values in the nanomolar range (Table I). In the imatinib-resistant LAMA84-R cell line nilotinib was also more effective than imatinib underlining nilotinib's high potency [11,12,21] (Table I). Only the K562-R cell line, in which several different resistance mechanisms are probably involved [7,21,31] showed a high resistance to both imatinib and nilotinib (IC50 values >20,000 nM) (Table I). With the exception of Ba/F3<sub>T315I</sub> single agent nilotinib was also active in the highly imatinib-resistant Ba/F3<sub>E255K</sub> and Ba/F3<sub>E255V</sub> cell lines, which is consistent with previous findings [11,28]. Monotherapy with established chemotherapeutic agents resulted in variable antiproliferative effects in the investigated cell lines. Interestingly, in both the K562 and LAMA84 pair higher concentrations of the applied intercalating drugs and etoposide were required for growth inhibition of the imatinib-resistant cells implying cross-resistance (Table I). Since daunorubicin, etoposide and mitoxantrone are substrates for the P-glycoprotein (Pgp) mediated drug efflux [32-34], the known increased Pgp activity of these imatinib-resistant cell lines is one possible explanation [7,21]. Cytarabine which displayed no antiproliferative effects in the tested dose range in imatinib-resistant LAMA84-R and K562-R cells (Table I), however, has not been demonstrated to be a Pgp substrate [35].

Combination therapy employing nilotinib and classical chemotherapeutic drugs led to improved antileukemic effects. In imatinib-resistant LAMA84-R cells these effects resulted either from synergism (CI values <1) or potentiation of nilotinib activity (Figure 1). In the imatinib-resistant K562-R cells synergistic interactions could be observed at a lesser extent as compared to the imatinib-sensitive counterpart (Figure 2). In addition, the applied drug combinations acted synergistically also in Ba/F3 cells expressing defined imatinib-resistant BCR-ABL mutants. However, in T315I carrying cells, conferring complete resistance to imatinib [11], high doses of nilotinib were required to assess the synergistic interaction (>25,000 nM) limiting the clinical significance (Figure 3).

The antiproliferative effects of nilotinib are associated with induction of apoptosis [11,36]. In our study we investigated the pro-apoptotic effects in imatinib-resistant cells. Since clinically isolated BCR-ABL kinase domain mutants show a varying incidence and resistance to imatinib [6,11,37], we gave preference to the imatinib-resistant Ba/F3<sub>T315I</sub> and Ba/F3<sub>E255K</sub> cell lines harboring the more common BCR-ABL mutants with different levels of imatinib resistance in our experiments. Regarding combination treatment the apoptosis results in Figure 4 appear to be inconsistent with the synergistic effects observed in the cell proliferation assays (Figure 1-3). In our experiments the extent of apoptosis was defined as the proportion of early apoptotic cells (Annexin V<sup>+</sup>/PI<sup>-</sup>) which in contrast to the MTT assays

shows no direct correlation to the viable cell number [38]. The corresponding fractions of dead (necrotic) cells (annexin V+/PI+) were considerably higher and displayed a stronger correlation to the cell proliferation experiments (data not shown). In our experiments a significant increase in the number of early apoptotic cells as compared to the respective monotherapies could only be observed in imatinib-resistant Ba/F3<sub>T315I</sub> and LAMA84-R cells for the combinations nilotinib plus daunorubicin and nilotinib plus mitoxantrone, respectively, signifying the potential of the applied intercalating drugs to enhance nilotinib-induced apoptosis (Figure 4).

The underlying molecular mechanisms of the synergistic antiproliferative and pro-apoptotic effects of tyrosine kinase inhibitors in combination with classic antineoplastic agents are poorly investigated. Chow et al. [39] could show that the pro-apoptotic activity of nilotinib is not restricted to BCR-ABL, c-Kit, or PDGFR-positive cells. Nilotinib-induced apoptosis in cell lines of lymphatic origin was shown to critically rely on activation of caspase-6 and caspase-9 and differential expression of Src-kinases [39]. With regard to our results in Ba/F3<sub>T315I</sub> cells, originally derived from a murine pro B cell line [40] and showing no or only negligible expression of c-Kit or PDGFR, one could speculate that nilotinib is able to exert BCR-ABL independent pro-apoptotic effects which are only evident after sensitization by daunorubicin. Furthermore, the possibility of a physically altered interaction between nilotinib and the kinase domain of BCR-ABL after sensitization by standard chemotherapy allowing nilotinib to bind to the mutated T315I target cannot be ruled out either. In a recent report, Tiwari et al. [41] could demonstrate that nilotinib is able to reverse multidrug resistance by inhibiting the activity of ABCB1/Pgp and ABCG2/BCRP/MXR transporters. In one of our previous studies comprising functional rhodamine 123 efflux assays we could show that imatinib-sensitive LAMA84 cells displayed a lower Pgp activity than -resistant LAMA84-R cells, whereas K562 exhibited negligible and K562-R cells low Pgp activity [21]. Consequently, in these cell lines the observed synergy between nilotinib and the investigated agents, which with the exception of cytarabine are substrates for the Pgp mediated drug efflux [32-35], may be attributed to the inhibition of Pgp by nilotinib.

The drug concentrations applied in our *in vitro* synergy experiments were primarily selected to enable a reliable analysis according to the Chou and Talalay method, i.e. around the IC50 *in vitro*. Of course, it is of great relevance, whether these concentrations are also achievable *in vivo* and the respective synergistic effects can be expected in a clinical setting. Zhou et al. reported a steady state C<sub>max</sub> of 2,160.7 ng/mL (corresponding to 4,081 nM) in CML patients treated with the standard dose of nilotinib 400 mg twice daily [42]. For daunorubicin,

depending on the drug formulation varying plasma concentration can be observed. Feldman et al. [43] demonstrated a  $C_{max}$  of  $30,185 \pm 6,198$  ng/mL ( $57,221 \pm 11,749$  nM) in patients treated with a liposomal daunorubicin formulation. In the work of Canal et al. [44] the mean maximum plasma concentration of mitoxantrone reached  $6,429 \pm 2,427$   $\mu$ g/L ( $14,464 \pm 5,460$  nM) at maximum tolerated dose ( $90$  mg/m<sup>2</sup>) versus  $789 \pm 158$   $\mu$ g/L ( $1,775 \pm 355$  nM) after administration of  $15$  mg/m<sup>2</sup>. In 14 patients, who received the standard dose of  $100$  mg/m<sup>2</sup> etoposide, peak and trough serum concentrations of  $18.5$   $\mu$ g/mL ( $31,433$  nM) and  $0.2$   $\mu$ g/mL ( $340$  nM), respectively, could be observed [45]. In patients with relapsed AML or a blast crisis of CML steady-state plasma levels of cytarabine ranged between  $7,000$  and  $24,000$  nM after infusion at a dose rate of  $250$  mg/m<sup>2</sup>/h for  $36$  to  $72$  h [46]. Thus, with the exception of K562-R and Ba/F3<sub>T315I</sub> cells, the concentrations used in our *in vitro* studies are achievable in a clinical setting (Table I).

Nilotinib is approved for imatinib-resistant and -intolerant CML patients in the chronic and accelerated phase of the disease [13,14]. The newer studies report hematologic and cytogenetic responses to nilotinib in blast crisis, although the response rates are as expected lower [15,47]. With nilotinib, as a representative of second-generation TKI, displaying synergistic or additive drug interactions with a number of established chemotherapeutics in CML cells, the preclinical data reported in this work support combination treatment regimens for clinical testing. Based on our previous clinical experience with imatinib-based combination treatment in myeloid blast crisis patients [30] we propose a modern treatment concept for this patient group beginning with an induction treatment with a well tolerated chemotherapy regimen, e.g. mitoxantrone/etoposide (NOVE regimen) given along with nilotinib. Upon response to induction treatment, eligible patients should be assigned to a consolidation with allogeneic stem cell transplantation. Patients not eligible for allogeneic transplantation but fit enough to receive an intermediate-intensive chemotherapy treatment can be offered an alternative consolidation with e.g. intermediate-dose cytarabine combined with nilotinib. After completion of consolidation, a life-long maintenance treatment with nilotinib can be expected to be advantageous for patients not receiving an allogeneic transplant and therefore still harboring a residual CML clone. Regarding the low incidence of CML blast crisis under efficient imatinib treatment nowadays a concerted multicenter effort is needed to implement such a treatment concept in order to yield patient recruitment sufficient for further analysis.

## Acknowledgments

We thank Bernhard Berkus, Hans-Jürgen Engel and especially Carmen Hoppstock (German Cancer Research Center, Heidelberg, Germany) for their expert technical assistance and Dr. E. Buchdunger (Novartis, Basel, Switzerland) for supplying nilotinib. We are also grateful to Professor Dr. Junia Melo (Hammersmith Hospital, London, UK) and to Professor Dr. Justus Duyster (Department of Internal Medicine III, Technical University of Munich, Munich, Germany) for providing the imatinib-resistant K562-R/LAMA84-R and Ba/F3 cell lines, respectively. We also thank Dr. Christine Volk for critically reading the manuscript.

**Authors' contributions:**

A.R. designed research, performed research, analyzed data, wrote manuscript. S.F. designed research, approved manuscript. W.J.Z. assisted with interpretation and analysis of data. A.D.H. assisted with interpretation and analysis of data, approved manuscript. J.T. wrote manuscript and is responsible for conception of research and integrity and analysis of data.

**Disclosures:** None

## REFERENCES

- 1 Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. *Science*. 1960;132:1497-1501.
- 2 Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature*. 1973;243:290-3.
- 3 Goldman JM, Melo JV. Chronic myeloid leukemia--advances in biology and new approaches to treatment. *N Engl J Med*. 2003;349:1451-64.
- 4 Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. *Science*. 1990;247:1079-82.
- 5 Peggs K, Mackinnon S. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia. *N Engl J Med*. 2003;348:1048-50.
- 6 Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. *Blood*. 2005;105:2640-53.
- 7 Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST571: diverse mechanisms of resistance. *Blood*. 2000;96:1070-9.
- 8 Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science*. 2001;293:876-80.
- 9 von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. *Lancet*. 2002;359:487-91.
- 10 Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. *Semin Hematol*. 2007;44:15-24.
- 11 Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. *Cancer Cell*. 2005;7:129-41. Erratum in: *Cancer Cell*. 2005;7:399.
- 12 Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M.

- AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. *Clin Cancer Res.* 2005;11:4941-7.
- 13 Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. *N Engl J Med.* 2006;354:2542-51.
- 14 Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. *Blood.* 2007;110:3540-6.
- 15 Giles FJ, Larson RA, Kantarjian HM, le Coutre P, Baccarani M, Haque A, Gallagher N, Ottmann OG. Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib. *Blood.* 2007;110:1025 abstract.
- 16 Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. *Blood.* 2007;109:3207-13.
- 17 Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, Bandini G, Carreras E, Vernant JP, Bosi A, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. *Bone Marrow Transplant.* 1993;12:509-16.
- 18 Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. *Leukemia.* 2001;15:342-7.
- 19 Topaly J, Fruehauf S, Ho AD, Zeller WJ. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. *Br J Cancer.* 2002;86:1487-93.
- 20 Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. *Br J Haematol.* 2002;119:3-14.

- 21 Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. *Leukemia*. 2005;19:1198-206.
- 22 Radujkovic A, Topaly J, Fruehauf S, Zeller WJ. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. *Anticancer Res*. 2006;26:2169-77.
- 23 Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. *Blood*, 2000;96:3195-9.
- 24 Liu WM, Stimson LA, Joel SP. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. *Br J Cancer*. 2002;86:1472-8.
- 25 Marley SB, Davidson RJ, Goldman JM, Gordon MY. Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. *Br J Haematol*. 2002;116:162-5.
- 26 Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. *Exp Oncol*. 2007;29:126-31.
- 27 Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. *Blood*. 2001;97:1999-2007.
- 28 von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). *Blood*. 2006;108:1328-33.
- 29 Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Regul*. 1984;22:27-55.
- 30 Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, Müller MC, Schuld P, Balleisen L, Hehlmann R, Ho AD, Hochhaus A. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. *Cancer*. 2007;109:1543-9.
- 31 Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistrini V, Andreoni F, Scapoza L, Formelli F,



- Gambacorti-Passerini C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. *Cancer Res.* 2006;66:11314-22.
- 32 Michieli M, Michelutti A, Damiani D, Ermacora A, Masolini P, Stocchi R, Russo D. Amifostine does not inhibit the toxic effects of anthracycline derivatives or mitoxantrone on MDR tumor cell lines. *Leuk Lymphoma.* 2001;42:721-9.
- 33 Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. *Cancer Chemother Pharmacol.* 2003;51:297-305.
- 34 Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. *Curr Pharm Des.* 2006;12:273-86.
- 35 Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G, et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. *Leukemia.* 1994;8:465-75.
- 36 Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, Manley PW, Mestan J, Fabbro D, Jiang J, Hall-Meyers E, Callahan L, DellaGatta JL, Kung AL, Griffin JD. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. *Blood.* 2007;109:2112-20.
- 37 Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. *Leukemia.* 2004;18:1321-31.
- 38 Pieters R, Huisman DR, Leyva A, Veerman AJ. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. *Cancer Lett.* 1988;41:323-32.
- 39 Chow KU, Nowak D, Trepohl B, Hochmuth S, Schneider B, Hoelzer D, Mitrou PS, Bergmann L, Ottmann OG, Boehrer S. The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines. *Leuk Lymphoma.* 2007;48:1379-88.
- 40 Palacios R, Steinmetz M. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. *Cell.* 1985;41:727-34.
- 41 Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity

- of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. *Biochem Pharmacol.* 2009;78:153-61.
- 42 Zhou L, Meng F, Yin O, Wang J, Wang Y, Wei Y, Hu P, Shen Z. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. *Clin Ther.* 2009;31:1568-75.
- 43 Feldman E, Lancet J, Kolitz JE, Trang JM, Mayer L, Louie AC. Pharmacology of CPX-351: a nano-scale liposomal fixed molar ratio cytarabine-daunorubicin for patients with advanced leukemia. *Haematologica* 2009;94[suppl.2]:67 abstract 0174
- 44 Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, Bugat R. Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. *Cancer Res.* 1993;53:4850-4.
- 45 Kato Y, Nishimura S, Sakura N, Ueda K. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. *Pediatr Int.* 2003;45:74-9.
- 46 Spriggs DR, Robbins G, Arthur K, Mayer RJ, Kufe D. Prolonged high dose ARA-C infusions in acute leukemia. *Leukemia.* 1988;2:304-6.
- 47 Giles FJ, le Coutre P, Bhalla KN, Ossenkoppele G, Alimena G, Haque A, Neil Gallagher N, Kantarjian HM. Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC). *Blood.* 2007;110:1029 abstract.

## FIGURE LEGENDS

### Figure 1. Analysis of drug interactions in imatinib-sensitive and -resistant LAMA84 cells.

[a] Imatinib-sensitive LAMA84 cells displayed antagonistic ( $CI > 1$ ) effects upon combination treatment with nilotinib and daunorubicin.

[c, g] Treatment of imatinib-sensitive LAMA84 cells with combinations of nilotinib plus mitoxantrone and nilotinib plus cytarabine showed synergistic effects ( $CI < 1$ ) above affected fractions approximately  $> 0.6$ .

[e] For the combination nilotinib plus etoposide additive ( $CI \sim 1$ ) antiproliferative effects were discernible in LAMA84 cells.

[b, d, f] In imatinib-resistant LAMA84-R cells synergistic effects were observable for the combination nilotinib plus daunorubicin ( $Fa \leq 0.7$ ), nilotinib plus mitoxantrone ( $0.4 \leq Fa < 0.8$ ) and nilotinib plus etoposide ( $Fa \geq 0.65$ ).

[h] Non-cytotoxic doses of cytarabine potentiated nilotinib activity in LAMA84-R cells (cf. Materials and Methods)

CI: combination index; Fa: fraction affected. The dotted line at  $CI = 1$  in Figure 1 a-g represents additive,  $> 1$  represents antagonistic,  $< 1$  represents synergistic effects of the applied drug combinations. The dashed line in a-g represents the standard deviation (s.d.). The dotted line at 1 in h represents the relative nilotinib  $IC_{50}$  value;  $> 1$  indicates inhibition,  $< 1$  indicates potentiation of nilotinib activity. The error bars in h represent the standard deviation (s.d.).  $n = 5$  for each experiment. \* $p < 0.05$ , \*\* $p < 0.01$ .

### Figure 2. Analysis of drug interactions in imatinib-sensitive and -resistant K562 cells.

[a, c, e] In imatinib-sensitive K562 cells synergistic effects were detectable for the combination nilotinib plus daunorubicin ( $Fa \geq 0.4$ ), nilotinib plus mitoxantrone ( $Fa > 0.3$ ) and nilotinib plus etoposide ( $Fa < 0.8$ ).

[b, f] The combinations nilotinib plus daunorubicin and nilotinib plus etoposide acted synergistically in imatinib-resistant K562 cells at  $0.35 < Fa < 0.9$  and  $0.45 < Fa < 0.75$ , respectively.

[d] Treatment of K562-R cells with nilotinib plus mitoxantrone displayed at best additive effects ( $CI \sim 1$  at  $0.4 < Fa < 0.9$ ).

[g, h] Cytarabine showed no significant potentiation of nilotinib activity in both imatinib-sensitive and -resistant K562 cells.

CI: combination index; Fa: fraction affected. The dotted line at CI = 1 in Figure 1 a-g represents additive, > 1 represents antagonistic, < 1 represents synergistic effects of the applied drug combinations. The dashed line in a-f represents the standard deviation (s.d.). The dotted line at 1 in g and h represents the relative nilotinib IC50 value; > 1 indicates inhibition, < 1 indicates potentiation of nilotinib activity. The error bars in g and h represent the standard deviation (s.d.). n = 5 for each experiment.

**Figure 3. Analysis of drug interactions in imatinib-sensitive Ba/F3<sub>wt</sub> and imatinib-resistant Ba/F3<sub>E255K</sub>, Ba/F3<sub>E255V</sub> and Ba/F3<sub>T315I</sub> cell lines.**

[a, b] Both investigated combinations nilotinib plus daunorubicin and nilotinib plus mitoxantrone showed synergism in Ba/F3<sub>wt</sub> above affected fractions  $\geq 0.45$  and  $> 0.3$ , respectively.

[c, e, g] Co-treatment with nilotinib and daunorubicin resulted in synergistic effects in all investigated imatinib-resistant Ba/F3<sub>E255K</sub>, Ba/F3<sub>E255V</sub> and Ba/F3<sub>T315I</sub> cell lines above Fa $\geq 0.65$ , Fa $> 0.15$  and Fa $> 0.7$ , respectively.

[d, f, h] Synergism could also be observed for the combination nilotinib plus mitoxantrone above affected fractions  $> 0.7$  and  $\geq 0.2$  in Ba/F3<sub>E255K</sub> and both Ba/F3<sub>E255V</sub> and Ba/F3<sub>T315I</sub> cells, respectively.

CI: combination index; Fa: fraction affected. The dotted line at CI = 1 represents additive, > 1 represents antagonistic, < 1 represents synergistic effects of the applied drug combinations. The dashed line represents the standard deviation (s.d.). n = 5 for each experiment.

**Figure 4. Induction of apoptosis in imatinib-resistant cell lines after treatment with different concentrations of single agent nilotinib, daunorubicin and mitoxantrone or with combinations.**

[a] Combination treatment of imatinib-resistant K562-R and LAMA84-R cell lines increased early apoptotic cell fractions (annexin V<sup>+</sup> / PI<sup>-</sup> cells) as compared to the respective monotherapies. A significant increase of the early apoptotic cell fraction could be demonstrated for the combination nilotinib plus mitoxantrone in the LAMA84-R cell line.


[b] In imatinib-resistant Ba/F3<sub>E255K</sub> and Ba/F3<sub>T315I</sub> cells similar effects were discernible. Significant enhancement of apoptosis could only be observed in the Ba/F3<sub>T315I</sub> cell line upon treatment with the combination nilotinib plus daunorubicin.


(\*p<0.05) The error bars represent the standard deviation (s.d.). n = 3 for each experiment.

**Table I.** Effects of single agent nilotinib and established chemotherapeutic drugs on the cell growth of different BCR-ABL-positive imatinib-sensitive and -resistant cell lines after 48 h treatment.


Cell line	IC <sub>50</sub> (nM), mean ± s.d. (concentration range tested) <sup>a</sup>									
	Nilotinib		Daunorubicin		Mitoxantrone		Etoposide		Cytarabine	
<b>LAMA84</b>	11±2	(2-32)	344±23	(62.5-1,000)	365±107	(62.5-1000)	3,178±1,054	(625-10,000)	175±23	(32-512)
<b>LAMA84-R</b>	124±31	(20-320)	7,219±1,118	(1250-20,000)	3,783±1,040	(625-10000)	4,017±432	(625-10,000)	n/e <sup>b</sup>	(5,000-80,000)
<b>K562</b>	34±9	(6.25-100)	1,634±524	(312.5-5,000)	6,065±1,186	(1,250-20,000)	22,745±2,914	(4,000-64,000)	n/e	(5,000-80,000)
<b>K562-R</b>	21,972±1,598	(6,250-100,000)	2,363±177	(625-10,000)	6,969±1,311	(2,000-32,000)	30,012±5,718	(8,000-128,000)	n/e	(5,000-80,000)
<b>Ba/F3wt</b>	23±6	(2.5-40)	106±26	(12.5-200)	4±1	(0.4-6.4)	n.d. <sup>c</sup>		n.d.	
<b>Ba/F3E255K</b>	365±41	(62.5-1000)	88±6	(15.625-250)	3±1	(0.5-8)	n.d.		n.d.	
<b>Ba/F3E255V</b>	791±189	(100-1,600)	99±6	(12.5-200)	3±1	(0.4-6.4)	n.d.		n.d.	
<b>Ba/F3T315I</b>	23,582±1,923	(6,250-100,000)	92±20	(25-400)	2±1	(0.5-8)	n.d.		n.d.	

Mean values (nM) ± 1 standard deviation (s.d.) are given, n = 5 each. a) Concentrations were doubled with each increment. b) Not evaluable, insufficient dose–response correlation in the median effect plot (r<0.95). c) Not determined.






Combination with





**a****b**